Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 56

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 56
---
 create competing priorities;                                  |

| • | partners may delay clinical trials, provide insufficient funding for a clinical trial, stop a clinical                                       
 trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical 
 testing;                                                                                                                                     |

| • | a partner with marketing and distribution rights to one or more products may not commit sufficient resources 
 to the marketing and distribution of such product or products;                                               |

| • | disagreements with partners, including disagreements over proprietary rights, contract interpretation                                          
 or the preferred course of development, might cause delays or termination of the research, development or commercialization of product         
 candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, 
 any of which would be time-consuming and expensive;                                                                                            |

| • | partners may not properly maintain or defend our intellectual property rights or may use our proprietary                                   
 information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information 
 or expose us to potential litigation;                                                                                                      |

| • | partners may infringe the intellectual property rights of third parties, which may expose us to litigation 
 and potential liability; and                                                                               |

| • | agreements may be terminated and, if terminated, may result in a need for additional capital to pursue 
 further development or commercialization of the applicable product candidates.                         |

Agreements may not lead to
development or commercialization of product candidates in the most efficient manner, or at all. If any future partners of ours is involved
in a business combination, it could decide to delay, diminish or terminate the development or commercialization of any product candidate
licensed to it by us.

| 30 |

The commercial success of any of our product candidates is not guaranteed.

There can be no assurance
that any of our product candidates currently in development will be successfully developed into any commercially viable product or products
and/or be manufactured in commercial quantities at an acceptable cost or be marketed successfully and profitably. If we, or our partners,
encounter delays at any stage, and fail successfully to address such delays, it may have a material adverse effect on our business, financial
condition and prospects. In addition, our success will depend on the market’s acceptance of these products and there can be no guarantee
that this acceptance will be forthcoming or that our technologies will succeed as an alternative to competing products. If a market fails
to develop or develops more slowly than anticipated, we may be unable to recover